Company news

Longeveron Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer’s Disease With Lomecel-B™

December 5, 2023

Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update

November 9, 2023

Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023

November 2, 2023

Longeveron Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

October 12, 2023

Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

October 11, 2023

Longeveron Announces Positive Top-Line Results for Lomecel-B™ in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer’s Disease

October 4, 2023

Longeveron Rights Offering Subscription Period Begins

August 21, 2023

Longeveron Rights Offering Declared Effective and Calendar Finalized

August 15, 2023

Longeveron Announces Pricing for Rights Offering and Expected Calendar

August 13, 2023

Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update

August 10, 2023

Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome

August 10, 2023

Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions

August 7, 2023

Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023

August 6, 2023

Longeveron Appoints Lisa Locklear as Chief Financial Officer

July 19, 2023

Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer

July 10, 2023

Longeveron Files Registration Statement for Rights Offering

June 26, 2023

Longeveron Welcomes Three New Prominent Board Members

June 12, 2023

Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 11, 2023

Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome

May 8, 2023

Longeveron to Announce First Quarter 2023 Financial Results on May 12, 2023

May 7, 2023

Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B™ for Aging-Related Frailty in Japan

April 18, 2023

Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

March 9, 2023

Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023

March 5, 2023

Longeveron Appoints Wa’el Hashad as Chief Executive Officer

February 27, 2023

Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal

January 18, 2023

Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones

January 5, 2023

Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 13, 2022

Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’s Disease

November 9, 2022

Longeveron to Announce Third Quarter 2022 Financial Results on November 14, 2022

November 6, 2022

Longeveron Names Jerome Bailey Vice President of Business Operations

September 14, 2022

Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy Through Levels of Vascular Biomarker

August 24, 2022

Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results

August 11, 2022

Longeveron to Announce Second Quarter 2022 Financial Results on August 12, 2022

August 7, 2022

Longeveron Announces Abstract Accepted for Presentation at the Alzheimer’s Association International Conference (AAIC)

July 6, 2022

Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results

May 12, 2022

Longeveron to Announce First Quarter 2022 Financial Results on May 13, 2022

May 8, 2022

Longeveron Announces CEO Transition

May 8, 2022

Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer’s Trial

April 12, 2022

Longeveron Expands Executive Leadership Team; Appoints K. Chris Min, M.D., Ph.D. as Chief Medical Officer

April 4, 2022

Longeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress

March 10, 2022

Longeveron to Announce Fourth Quarter and Full Year 2021 Financial Results, on March 11, 2022

March 6, 2022

Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors

February 16, 2022

Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging

January 11, 2022

Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease

January 4, 2022

Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)

December 5, 2021

Longeveron Inc. Announces Closing of a $20.5 Million Private Placement

December 2, 2021

Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement

November 30, 2021

Longeveron Announces Phase 2 Clinical Trial in Japan to Test Safety and Efficacy of Lomecel-B on Aging Frailty Patients

November 29, 2021

U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition

November 17, 2021

Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2021 Financial Results

November 11, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 12 decks. Every deck is listed under its year.